Every baby born must ensure healthy physical and mental development. Therefore, from birth, newborns need to have screening tests to help detect diseases early and find timely treatment to reduce mortality rates and help children have a good start.

Newborn screening programs aim to detect metabolic disorders in children early, helping to prevent dangerous complications and giving children a normal, healthy life.

Newborn screening aims to proactively detect, intervene and treat early diseases, metabolic and genetic disorders during the fetal and neonatal stages. The benefits of newborn screening are to help children develop normally and reduce the number of people with disabilities and intellectual disabilities.

Congenital hypothyroidism is defined as a significant reduction or loss of thyroid function in a newborn baby, affecting the child's growth, physical and mental development. However, if detected and treated early, the child will have the opportunity to develop normally and healthily.

The 17-OHP test helps doctors detect congenital adrenal hyperplasia, thereby providing timely treatment to avoid affecting the patient's life and quality of life.

17-OHP measurement is the first choice test for diagnosing congenital adrenal hyperplasia. The DIAsource ELISA assay is performed using venous blood as a specimen.

Currently, the 17-OHP test is considered an effective method in early detection of the risk of congenital adrenal hyperplasia in infants and adults, to provide timely treatment methods.